200 related articles for article (PubMed ID: 8321240)
21. Differential inhibition of signaling pathways by dominant-negative SH2/SH3 adapter proteins.
Tanaka M; Gupta R; Mayer BJ
Mol Cell Biol; 1995 Dec; 15(12):6829-37. PubMed ID: 8524249
[TBL] [Abstract][Full Text] [Related]
22. Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation.
Mayer BJ; Hanafusa H
J Virol; 1990 Aug; 64(8):3581-9. PubMed ID: 1695251
[TBL] [Abstract][Full Text] [Related]
23. A potential SH3 domain-binding site in the Crk SH2 domain.
Anafi M; Rosen MK; Gish GD; Kay LE; Pawson T
J Biol Chem; 1996 Aug; 271(35):21365-74. PubMed ID: 8702917
[TBL] [Abstract][Full Text] [Related]
24. The product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner.
Ribon V; Hubbell S; Herrera R; Saltiel AR
Mol Cell Biol; 1996 Jan; 16(1):45-52. PubMed ID: 8524328
[TBL] [Abstract][Full Text] [Related]
25. Downstream of Crk adaptor signaling pathway: activation of Jun kinase by v-Crk through the guanine nucleotide exchange protein C3G.
Tanaka S; Ouchi T; Hanafusa H
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2356-61. PubMed ID: 9122199
[TBL] [Abstract][Full Text] [Related]
26. The SH2- and SH3-containing Nck protein transforms mammalian fibroblasts in the absence of elevated phosphotyrosine levels.
Chou MM; Fajardo JE; Hanafusa H
Mol Cell Biol; 1992 Dec; 12(12):5834-42. PubMed ID: 1280326
[TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts.
Birge RB; Fajardo JE; Reichman C; Shoelson SE; Songyang Z; Cantley LC; Hanafusa H
Mol Cell Biol; 1993 Aug; 13(8):4648-56. PubMed ID: 7687742
[TBL] [Abstract][Full Text] [Related]
28. DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane.
Hasegawa H; Kiyokawa E; Tanaka S; Nagashima K; Gotoh N; Shibuya M; Kurata T; Matsuda M
Mol Cell Biol; 1996 Apr; 16(4):1770-6. PubMed ID: 8657152
[TBL] [Abstract][Full Text] [Related]
29. Binding of transforming protein, P47gag-crk, to a broad range of phosphotyrosine-containing proteins.
Matsuda M; Mayer BJ; Fukui Y; Hanafusa H
Science; 1990 Jun; 248(4962):1537-9. PubMed ID: 1694307
[TBL] [Abstract][Full Text] [Related]
30. Src homology domains of phospholipase C gamma1 inhibit nerve growth factor-induced differentiation of PC12 cells.
Bae SS; Lee YH; Chang JS; Galadari SH; Kim YS; Ryu SH; Suh PG
J Neurochem; 1998 Jul; 71(1):178-85. PubMed ID: 9648864
[TBL] [Abstract][Full Text] [Related]
31. The SH3 domain of Crk binds specifically to a conserved proline-rich motif in Eps15 and Eps15R.
Schumacher C; Knudsen BS; Ohuchi T; Di Fiore PP; Glassman RH; Hanafusa H
J Biol Chem; 1995 Jun; 270(25):15341-7. PubMed ID: 7797522
[TBL] [Abstract][Full Text] [Related]
32. Physical and functional interactions between SH2 and SH3 domains of the Src family protein tyrosine kinase p59fyn.
Panchamoorthy G; Fukazawa T; Stolz L; Payne G; Reedquist K; Shoelson S; Songyang Z; Cantley L; Walsh C; Band H
Mol Cell Biol; 1994 Sep; 14(9):6372-85. PubMed ID: 7520528
[TBL] [Abstract][Full Text] [Related]
33. The v-Crk oncogene enhances cell survival and induces activation of protein kinase B/Akt.
Stam JC; Geerts WJ; Versteeg HH; Verkleij AJ; van Bergen en Henegouwen PM
J Biol Chem; 2001 Jul; 276(27):25176-83. PubMed ID: 11323409
[TBL] [Abstract][Full Text] [Related]
34. Role of Crk oncogene product in physiologic signaling.
Kiyokawa E; Mochizuki N; Kurata T; Matsuda M
Crit Rev Oncog; 1997; 8(4):329-42. PubMed ID: 9622053
[TBL] [Abstract][Full Text] [Related]
35. v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation.
Akagi T; Shishido T; Murata K; Hanafusa H
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7290-5. PubMed ID: 10852971
[TBL] [Abstract][Full Text] [Related]
36. Activation of c-Src in cells bearing v-Crk and its suppression by Csk.
Sabe H; Okada M; Nakagawa H; Hanafusa H
Mol Cell Biol; 1992 Oct; 12(10):4706-13. PubMed ID: 1383688
[TBL] [Abstract][Full Text] [Related]
37. Iterative tyrosine phosphorylation controls non-canonical domain utilization in Crk.
Sriram G; Jankowski W; Kasikara C; Reichman C; Saleh T; Nguyen KQ; Li J; Hornbeck P; Machida K; Liu T; Li H; Kalodimos CG; Birge RB
Oncogene; 2015 Aug; 34(32):4260-9. PubMed ID: 25381819
[TBL] [Abstract][Full Text] [Related]
38. SH2 and SH3-containing adaptor proteins: redundant or independent mediators of intracellular signal transduction.
Birge RB; Knudsen BS; Besser D; Hanafusa H
Genes Cells; 1996 Jul; 1(7):595-613. PubMed ID: 9078388
[TBL] [Abstract][Full Text] [Related]
39. Crk family adaptor proteins trans-activate c-Abl kinase.
Shishido T; Akagi T; Chalmers A; Maeda M; Terada T; Georgescu MM; Hanafusa H
Genes Cells; 2001 May; 6(5):431-40. PubMed ID: 11380621
[TBL] [Abstract][Full Text] [Related]
40. Two species of human CRK cDNA encode proteins with distinct biological activities.
Matsuda M; Tanaka S; Nagata S; Kojima A; Kurata T; Shibuya M
Mol Cell Biol; 1992 Aug; 12(8):3482-9. PubMed ID: 1630456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
